| Literature DB >> 28730644 |
Danila Seidel1, Luisa A Durán Graeff1, Maria J G T Vehreschild1,2,3, Hilmar Wisplinghoff4,5,6, Maren Ziegler4, J Janne Vehreschild1,2,3, Blasius Liss7, Axel Hamprecht5, Philipp Köhler1,8, Zdenek Racil9, Nikolay Klimko10, Donald C Sheppard11, Raoul Herbrecht12, Anuradha Chowdhary13, Oliver A Cornely1,8,14.
Abstract
Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope™ is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope™ was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope™ have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope™ registry.Entities:
Keywords: fungal infection; global cooperation; immunocompromised; orphan disease; registry
Mesh:
Year: 2017 PMID: 28730644 DOI: 10.1111/myc.12631
Source DB: PubMed Journal: Mycoses ISSN: 0933-7407 Impact factor: 4.377